

## STENTYS Reports 40% Increase in Revenues in Second Quarter of 2015

PRINCETON, N.J. and PARIS - July 8, 2015 - STENTYS (FR0010949404 - STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announces its revenues and cash position at June 30, 2015.

- **Quarterly revenues\***

€ thousands	Half year – 6 months			Quarter – 3 months		
	H1 2015	H1 2014	Var. %	Q2 2015	Q2 2014	Var. %
<b>Revenues</b>	<b>2,606.0</b>	1,934.0	+34.7%	<b>1,512.0</b>	1,080.0	+40.0%

\* Figures subject to a limited review

Following a promising first quarter (with sales up 28%), STENTYS continues on its growth momentum with revenues increasing by 40% to €1.5 million in the second quarter of 2015. This acceleration is the result of the launch of the Xposition® product line, STENTYS' new generation of self-apposing stent, during the month of May 2015. Combining the Sirolimus-eluting stent and the new delivery catheter that replicates the implantation technique of a conventional stent, Xposition has been well received by cardiologists.

Over the first half of 2015, STENTYS recorded sales of €2.6 million, a 34.7% increase.

- **Sound cash position**

At June 30, 2015, STENTYS' balance sheet remained solid with cash and equivalents of €12.7 million.

**Gonzague Issenmann, Chief Executive Officer and co-founder of STENTYS, comments:** "The launch of the Xposition line is progressing as planned. Our customers are delighted with the improvements to our product and we are very confident that the technology's adoption will continue and our growth will accelerate."

- **Upcoming financial report**

STENTYS expects to publish its financial results for the first half of 2015 on September 17, 2015.

### About STENTYS

STENTYS is developing and commercializing innovative solutions for the treatment of patients with complex artery disease. STENTYS' Self-Apposing® drug-eluting stents are designed to adapt to vessels with ambiguous or fluctuating diameters in order to prevent the malapposition problems associated with conventional stents. The APPOSITION clinical trials in the treatment of acute myocardial infarction showed a very low one year mortality rate and a faster arterial healing compared to conventional stents. The company's product portfolio also includes MiStent SES®, a coronary DES whose new drug delivery mechanism is designed to match vessel response, and is marketed through STENTYS' commercial network in Europe, the Middle East, Asia and Latin America. **More information is available at [www.stentys.com](http://www.stentys.com).**

### Safe Harbor Statements

This press release contains forward-looking statements about the Company that are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which it will operate in the future which may not be accurate. Such forward-looking statements involve known and unknown risks which may cause the Company's actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, risks associated with the development and commercialization of the Company's products, market acceptance of the Company's products, its ability to manage growth, the competitive environment in relation to its business area and markets, its ability to enforce and protect its patents and proprietary rights, uncertainties related to the U.S. FDA approval process, slower than expected rates of patient recruitment for clinical trials, the outcome of clinical trials, and other factors, including those described in the Section 4 "Risk Factors"

of the Company's 2013 Registration Document (document de référence) filed with the French Autorité des Marchés Financiers on October 29, 2014 under number D.14-1026 as such section may be updated from time to time.

**STENTYS**

Stanislas Piot

CFO

Tel.: +33 (0)1 44 53 99 42

[stan.p@stentys.com](mailto:stan.p@stentys.com)

**NewCap**

Investor Relations / Strategic Communications

Dusan Oresansky / Pierre Laurent

Tel.: +33 (0)1 44 71 94 93

[stentys@newcap.fr](mailto:stentys@newcap.fr)

**LifeSci Advisors LLC**

Andrew McDonald

Tel: +1.646.597.6987

[andrew@lifesciadvisors.com](mailto:andrew@lifesciadvisors.com)

STENTYS is listed on Comp. C of the Euronext Paris market

ISIN: FR0010949404 – Ticker: STNT